- FY25 revenue and PATMI were within expectations at 96%/97% of our FY25e estimates, respectively. 2H25 adjusted PATMI grew 4% YoY to S$36.4mn. Revenue in China and healthcare services contracted in 2H25. FY25 dividends rose 20% to 3 cents (84% payout).
- Hospital services registered a 9% growth in revenue and profits in 2H25. Driving revenue was a combination of higher prices, insurance channelling more patients and corporate accounts.
- We lower our FY26e PATMI by 8% to S$73mn. Our DCF target price of S$1.02 and NEUTRAL recommendation is maintained. Growth in Singapore is muted due to sluggish patient volumes. Price pressure from insurers and new government hospitals will be another headwind to raising patient bills. Losses in China are expected to narrow gradually. The lack of revenue momentum will cap the ability to scale up for operating leverage. Raffles Medical continues to generate attractive free cash flows of S$105mn in FY25 with a net cash balance sheet of S$261mn.
Continue Reading

